期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
慢性胃炎患者抗幽门螺杆菌感染治疗后幽门螺杆菌感染情况分析 被引量:5
1
作者 曹慧聪 《中国临床实用医学》 2021年第4期20-24,共5页
目的探讨慢性胃炎患者抗幽门螺杆菌感染治疗后幽门螺杆菌感染情况及炎症因子水平变化。方法选取2017年12月至2020年12月新泰市第三人民医院内一科收治的97例慢性胃炎患者,男54例,女43例,年龄(41.78±5.64)岁,年龄范围为25~63岁。采... 目的探讨慢性胃炎患者抗幽门螺杆菌感染治疗后幽门螺杆菌感染情况及炎症因子水平变化。方法选取2017年12月至2020年12月新泰市第三人民医院内一科收治的97例慢性胃炎患者,男54例,女43例,年龄(41.78±5.64)岁,年龄范围为25~63岁。采用随机数表法将患者随机分为单药治疗组(n=48)和联合治疗组(n=49)。单药治疗组患者给予泮托拉唑钠肠溶胶囊,联合治疗组在单药治疗组基础上给予阿莫西林胶囊和呋喃唑酮片。比较两组患者的临床治疗效果,胃黏膜评分,胃泌素水平,白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)水平及幽门螺杆菌感染转阴率。结果联合治疗组有效率[93.9%(46/49)]高于单药治疗组[79.2%(38/48)],差异有统计学意义(P<0.05)。治疗前两组患者胃黏膜评分及胃泌素水平比较,差异无统计学意义(P>0.05),治疗后两组患者胃黏膜评分[(1.59±0.26)分、(0.69±0.12)分]及胃泌素水平[(100.82±9.48)ng/L、(78.42±6.40)ng/L]低于治疗前[(2.36±0.46)分、(2.39±0.44)分,(132.94±12.65)ng/L、(132.89±12.75)ng/L],且联合治疗组低于单药治疗组,差异有统计学意义(P<0.05)。治疗前两组患者IL-6、TNF-α、IL-8水平比较,差异无统计学意义(P>0.05);治疗后两组患者IL-6[(24.74±2.95)pg/ml、(17.89±2.58)pg/ml]、TNF-α[(32.76±4.54)pg/ml、(28.49±3.49)pg/ml]、IL-8水平[(35.94±5.27)pg/ml、(27.48±4.14)pg/ml]低于治疗前[(27.76±3.86)pg/ml、(27.79±3.84)pg/ml,(42.94±5.65)pg/ml、(42.89±5.75)pg/ml,(46.82±5.89)pg/ml、(46.76±5.98)pg/ml],且联合治疗组低于单药治疗组,差异有统计学意义(P<0.05)。联合治疗组幽门螺杆菌感染转阴率[100%(49/49)]高于单药治疗组[77.1%(37/48)],差异有统计学意义(P<0.05)。结论慢性胃炎患者采用抗幽门螺杆菌感染治疗后能够改善治疗效果,提高幽门螺杆菌感染转阴率,降低血清炎症因子水平,有助于减轻患者临床症状。 展开更多
关键词 慢性胃炎患者 幽门杆菌感染 幽门螺杆菌感染情况 炎症因子
原文传递
Efficacy of a therapeutic strategy for eradication of Helicobacter pylori infection 被引量:4
2
作者 Giuliana Sereni Francesco Azzolini +8 位作者 Lorenzo Camellini Debora Formisano Francesco Decembrino Veronica Iori Cristiana Tioli Maurizio Cavina Francesco Di Mario Giuliano Bedogni Romano Sassatelli 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第33期4542-4548,共7页
AIM: To determine the efficacy of our therapeutic strategy for Helicobacter pylori (H. pylori) eradication and to identify predictive factors for successful eradication. METHODS: From April 2006 to June 2010, we retro... AIM: To determine the efficacy of our therapeutic strategy for Helicobacter pylori (H. pylori) eradication and to identify predictive factors for successful eradication. METHODS: From April 2006 to June 2010, we retrospectively assessed 2428 consecutive patients (1025 men, 1403 women; mean age 55 years, age range 18-92 years) with gastric histology positive for H. pylori infection referred to our unit for 13-C urea breath test(UBT), after first-line therapy with proton pump inhibitor (PPI) b.i.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 d. Patients who were still positive to UBT were recommended a second-line therapy (PPI b.i.d. + amoxicillin 1 g b.i.d. + tinidazole 500 mg b.i.d. for 14 d). Third choice treatment was empirical with PPI b.i.d. + amoxicillin 1 g b.i.d. + levofloxacin 250 mg b.i.d. for 14 d. RESULTS: Out of 614 patients, still H. pylori-positive after first-line therapy, only 326 and 19 patients respectively rechecked their H. pylori status by UBT after the suggested second and third-line regimens. "Per protocol" eradication rates for first, second and thirdline therapy were 74.7% (95% CI: 72.7%-76.4%), 85.3% (95% CI: 81.1%-89.1%) and 89.5% (95% CI: 74.9%-103%) respectively. The overall percentage of patients with H. pylori eradicated after two treatments was 97.8% (95% CI: 97.1%-98.4%), vs 99.9% (95% CI: 99.8%-100%) after three treatments. The study found that eradication therapy was most effective in patients with ulcer disease (P < 0.05, P = 0.028), especially in those with duodenal ulcer. Smoking habits did not significantly affect the eradication rate. CONCLUSION: First-line therapy with amoxicillin and clarithromycin produces an H. pylori eradication rate comparable or superior to other studies and secondline treatment can still be triple therapy with amoxicillin and tinidazole. 展开更多
关键词 Helicobacter pylori Eradication treatment Rescue therapy Eradication rate Triple therapy Firstline therapy Second-line therapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部